Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Adipose-derived stem cells for myocardial infarction.

Mazo M., Gavira JJ., Pelacho B., Prosper F.

Narrative Review on Cardiovascular Disease, published in J Cardiovasc Transl Res (2010) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Cardiovasc Transl Res (2010)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
21116883
DOI
10.1007/s12265-010-9246-y
Citations
38

Abstract (original English)

In recent years, stem cell treatment of myocardial infarction has elicited great enthusiasm upon scientists and physicians alike, thus making the finding of a suitable cell a compulsory subject for modern medicine. Due to its potential, accessibility and efficiency of harvesting, adipose tissue has become one of the most attractive sources of stem cells for regenerative therapies. The differentiation capacity and the paracrine activity of these cells has made them an optimal candidate for the treatment of a diverse range of diseases from immunological disorders as graft versus host disease to cardiovascular pathologies like peripheral ischemia. In this review, we will focus on the use of stem cells derived from adipose tissue for treatment of myocardial infarction, with special attention to their putative in vivo mechanisms of action.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsCell DifferentiationHumansMyocardial InfarctionMyocardiumMyocytes, CardiacParacrine CommunicationRecovery of FunctionRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research